Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis

Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

(2019) Helai P. Mohammad et al.   NATURE MEDICINE

Ferroptosis, a new form of cell death: opportunities and challenges in cancer

(2019) Yanhua Mou et al.   Journal of Hematology & Oncology

CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy

(2019) Weimin Wang et al.   NATURE

Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells

(2019) Shiyao Sui et al.   Cell Death & Disease

Molecular mechanisms of ferroptosis and its role in cancer therapy

(2019) Tao Xu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity

(2019) P. Khoueiry et al.   Epigenetics & Chromatin

Combination Therapy and the Evolution of Resistance: The Theoretical Merits of Synergism and Antagonism in Cancer

(2018) Elysia C. Saputra et al.   CANCER RESEARCH

Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis

(2018) Irina Ingold et al.   CELL

Regulation of lipid peroxidation and ferroptosis in diverse species

(2018) Marcus Conrad et al.   GENES & DEVELOPMENT

Metabolic networks in ferroptosis (Review)

(2018) Shihui Hao et al.   Oncology Letters

Harnessing synthetic lethality to predict the response to cancer treatment

(2018) Joo Sang Lee et al.   Nature Communications

Genetic Markers in Triple-Negative Breast Cancer

(2018) Zuzana Sporikova et al.   Clinical Breast Cancer

The Development of the Concept of Ferroptosis

(2018) Tal Hirschhorn et al.   FREE RADICAL BIOLOGY AND MEDICINE

Linking pBRD4 and PP2A inhibition in triple negative breast cancer.

(2018) Manuel Pedregal et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors

(2018) Isabella Faraoni et al.   Cancers

Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer

(2017) Alexander Beatty et al.   MOLECULAR CANCER THERAPEUTICS

Drug therapy: Exploiting synthetic lethality to improve cancer therapy

(2017) Diede Brunen et al.   Nature Reviews Clinical Oncology

Identification of ACSL4 as a biomarker and contributor of ferroptosis

(2016) Hua Yuan et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis

(2016) Nandini Verma et al.   CANCER RESEARCH

Mechanisms of ferroptosis

(2016) Jennifer Yinuo Cao et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

(2016) Shaokun Shu et al.   NATURE

ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition

(2016) Sebastian Doll et al.   Nature Chemical Biology

Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling

(2016) X Tang et al.   ONCOGENE

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

(2016) Ramiro Vázquez et al.   Oncotarget

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation

(2015) M Hayano et al.   CELL DEATH AND DIFFERENTIATION

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer

(2015) M van Geldermalsen et al.   ONCOGENE

Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease

(2015) Murugan Kalimutho et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer

(2015) Bharat Devapatla et al.   PLoS One

Regulation of Ferroptotic Cancer Cell Death by GPX4

(2014) Wan Seok Yang et al.   CELL

Bromodomain and Extraterminal Domain Inhibitors (BETi) for Cancer Therapy: Chemical Modulation of Chromatin Structure

(2014) J. Qi   Cold Spring Harbor Perspectives in Biology

Molecularly targeted therapies for metastatic triple-negative breast cancer

(2013) Soley Bayraktar et al.   BREAST CANCER RESEARCH AND TREATMENT

A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells

(2013) Fabio Petrocca et al.   CANCER CELL

Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target

(2013) Luika A. Timmerman et al.   CANCER CELL

Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8

(2013) Z. C. Hartman et al.   CANCER RESEARCH

Genetic Susceptibility to Triple-Negative Breast Cancer

(2013) K. N. Stevens et al.   CANCER RESEARCH

The phosphatidylinositol-transfer protein Nir2 binds phosphatidic acid and positively regulates phosphoinositide signalling

(2013) SoHui Kim et al.   EMBO REPORTS

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

(2012) Scott J. Dixon et al.   CELL

Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase

(2012) Liming Sun et al.   CELL

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Structural Requirements for VAP-B Oligomerization and Their Implication in Amyotrophic Lateral Sclerosis-associated VAP-B(P56S) Neurotoxicity

(2010) SoHui Kim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular Stratification of Triple-Negative Breast Cancers

(2010) C. M. Perou   ONCOLOGIST

Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis

(2010) Z. K. Pinnix et al.   Science Translational Medicine